Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924446 | 1.00 | MAPT (0.36) | MAPTSLC1A2MEN1CYP1A2ALOX15 | |
| SCHEMBL19080639 | 0.79 | GABRR1 (0.46) | MAPTMEN1KMT2AGABRR1 | |
| SCHEMBL7826374 | 0.79 | GABRR1 (0.46) | MAPTMEN1KMT2AGABRR1 | |
| SCHEMBL788723 | 0.74 | — | — | |
| SCHEMBL12201130 | 0.71 | GABRR1 (0.50) | KMT2AGABRR1 | |
| SCHEMBL21776710 | 0.71 | GABRR1 (0.39) | MEN1KMT2AGABRR1 | |
| SCHEMBL17972972 | 0.71 | GABRR1 (0.39) | KMT2AGABRR1 | |
| SCHEMBL13404483 | 0.71 | GABRR1 (0.39) | MEN1KMT2AGABRR1 | |
| SCHEMBL19655789 | 0.71 | GABRR1 (0.39) | MEN1KMT2AGABRR1 | |
| SCHEMBL12763445 | 0.70 | SLC1A2 (0.48) | SLC1A2MEN1CYP1A2ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3844159-B1 | NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-05-03 | — | — | EP | disclosed |
| US-20210323977-A1 | PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323977-A1 | PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ARG1, SSB, ARG2 | MAPT 3489/4885SLC1A2 1635/4885MEN1 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.